Home

Cidofovir vs foscarnet

Antiviral drugs final

Administration of cidofovir followed by foscarnet was associated with total clearance of human herpesvirus 6 infection. Cidofovir and foscarnet combination therapy may be beneficial for reducing mortality of (neutropenic) stem cell transplant recipients with human herpesvirus 6 encephalitis Ganciclovir, foscarnet, and cidofovir are antiviral drugs approved for use against cytomegalovirus (CMV) in adults by the US Food and Drug Administration. They have a broad spectrum of antiviral activity and are accordingly used for treatment of other viral infections, including herpes simplex viruses In vitro efficacy of idoxuridine and ganciclovir against FHV-1 was approximately equivalent and about twice that of cidofovir and penciclovir. Foscarnet appeared to be comparatively ineffective. Given the reasonable clinical efficacy of idoxuridine in cats infected with FHV-1, clinical trials of gan Learn about drug interactions between cidofovir iv and foscarnet iv and use the RxList drug interaction checker to check drug combinations. Drugs & Vitamins Drugs A-Z Drugs by Classification Drugs Comparison (Drug Vs. Drug) Vitamins & Supplements Drug Interaction Checker Pill Identifier

foscarnet to clinically asymptomatic patients. Cidofovir (CDV) is effective However, there are limited data on the pre-emptive use of CDV in CMV infections. primary pre-emptive therapy for CMV infections monitored by PCR-based assays. CDV was used at 5 mg/kg with probenecid and hydration, weekly for a maximum of Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach. We describe a girl treated with cidofovir for a.. The CMV Resistance: Ganciclovir, Foscarnet, Cidofovir sequencing assay is designed to detect identified mutations in the UL54 and UL97 genes of CMV. The use of genotypic sequencing offers a rapid turnaround time, a broad range of antiviral resistance information, and the ability to provide information concerning new drugs as they become.

Cidofovir and foscarnet for treatment of human herpesvirus

No se observó resistencia cruzada entre foscarnet y cidofovir con mutantes seleccionados por foscarnet. Los mutantes seleccionados por cidofovir presentaron mutación en el gen de ADN polimerasa y resistencia cruzada a ganciclovir, pero fueron sensibles a foscarnet. 5.2. Propiedades farmacocinética FOSCARNET sodium injection has the potential to chelate divalent metal ions, such as calcium and magnesium, to form stable coordination compounds. FOSCARNET sodium injection is a sterile, isotonic aqueous solution for intravenous administration only. The solution is clear and colorless

Cidofovir is a nucleotide analogue used primarily to treat CMV retinitis in patients with AIDS. However, cidofovir is also used to treat a number of DNA viruses including adenovirus. The main toxicity of cidofovir is nephrotoxicity, which can manifest as AKI, proteinuria, or a Fanconi-type syndrome with proximal tubular dysfunction Cidofovir is a white crystalline powder with an aqueous solubility of ≥ 170 mg/mL at pH 6-8 and a log P (octanol/aqueous buffer, pH 7.1) value of -3.3. VISTIDE is a sterile, hypertonic aqueous solution for intravenous infusion only. The solution is clear and colorless. It is supplied in clear glass vials, each containing 375 mg of anhydrous. The anti- CMV activities of cidofovir have been compared with those of ganciclovir and foscarnet. Regardless of the assay used, cidofovir was the most potent inhibitor of human CMV replication, including both wild-type and many ganciclovir -resistant and foscarnet -resistant strains (21) valganciclovir, foscarnet, and cidofovir are associated with significant toxicit ies. These findings, coupled with the emergence of resistance to available drugs (Lurain and Chou 2010; Komatsu e

Efficacy of cidofovir is similar to that of ganciclovir or foscarnet. Significant adverse effects, including renal failure, limit its use. Cidofovir may cause iritis or ocular hypotony (intraocular pressure ≤ 5 mm Hg) The standard regimen of cidofovir achieved a significantly longer median time to progression of CMV retinitis than a lower dosage (>280 vs 49 days) in a dose-finding study of patients with AIDS and CMV retinitis who had previously received anti-CMV treatment with ganciclovir, foscarnet or both drugs. In 1 of the 2 studies comparing immediate. No cross-resistance between foscarnet and cidofovir was seen with foscarnet-selected mutants. Cidofovir-selected mutants had a mutation in the DNA polymerase gene and were cross-resistant to ganciclovir, but susceptible to foscarnet. 5.2 Pharmacokinetic properties ‡ Resistant defined as refractory CMV and documentation of >1 CMV genetic mutations associated with resistance to ganciclovir, valganciclovir, foscarnet, and/or cidofovir Avery R. Randomized Phase 3 Open-Label Study of Maribavir vs Investigator-Assigned Therapy for Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients. Only foscarnet and cidofovir are readily available in Australia. Foscarnet (trisodium phosphonoformate hexahydrate) is a pyrophosphate analogue, which does not require phosphorylation (by viral TK) to inhibit DNA polymerase. As a result, it is active against aciclovir-resistant HSV with mutations in viral TK

Ganciclovir, Foscarnet, and Cidofovir: Antiviral Drugs Not

  1. Ganciclovir, foscarnet and cidofovir all have activity against HSV and VZV, but all also have substantial toxicities, especially when compared with acyclovir. These toxicities include myelosuppression (ganciclovir); metabolic derangements, including hypocalcemia, hypercalcemia, hypophosphatemia and hyperphosphatemia (foscarnet); and potentially.
  2. His CD4+ T-cell count was 24 cells/μl, and he had a poor response to highly active antiretroviral therapy. Over the course of 9 months, he was treated unsuccessfully with intravenous ganciclovir (highest dose, 10 mg/kg/day) and foscarnet (highest dose, 180 mg/kg/day). Systemic cidofovir induced hypotony and iritis in his left eye
  3. Summary Cidofovir is an antiviral medication that inhibits viral DNA polymerase. Remember that cidofovir does not require phosphorylation by viral kinases for activation, which means that it is not susceptible to the same resistance mechanisms as acyclovir and ganciclovir. You'll typically see cidofovir used in the second-line setting to treat patients with HSV or CMV strains that have.
  4. phosphonoformic acid, trisodium salt. Foscarnet sodium is a white, crystalline powder containing 6 equivalents of water of hydration with an empirical formula of Na 3 CO 5 P•6 H 2O and a . molecular weight of 300.1. The structural formula is: FOSCAVIR has the potential to chelate divalent metal ions, such as calcium and magnesium, t
  5. [3,4] UL97 mutations do not generally confer cross-resistance to either cidofovir or foscarnet. Mutations in the DNA polymerase gene UL54 may also lead to high-level resistance to ganciclovir and.
  6. Both GCV and foscarnet have been used and been shown to be effective in preventing CMV disease, particularly when pp65 antigenemia or PCR was used for monitoring.5,7,8,21-23 However, GCV is associated with significant bone marrow toxicity that may predispose to severe bacterial and fungal infections,24,25 and foscarnet can cause significant.

In vitro efficacy of ganciclovir, cidofovir, penciclovir

Like ganciclovir and foscarnet, cidofovir is administered initially in induction doses, followed by long-term maintenance therapy. However, in contrast to the daily infusions required with the other agents, induction doses of 5 mg/kg cidofovir are given once a week for 2 weeks, followed by maintenance doses of 5 mg/kg once every other week Acyclovir IV Foscarnet IV Ribavirin PO Valganciclovir PO Cidofovir IV Oseltamivir PO Valacyclovir PO Footnotes . Table of Contents Page 2 of 8 ANTIBIOTICS 1CrCl >50 mL/min CrCl1 30-49 mL/min 2CrCl1 310-29 mL/min CrCl1 <10 mL/min; HD CRRT (rate 2.5 L/hr Foscarnet is an organic pyrophosphate analog that reversibly inhibits pUL54 by blocking the pyrophosphate binding site 75 without incorporation into the elongating viral DNA . 76 High intracellular foscarnet levels are required to inhibit UL54. 77 Cidofovir is a nucleotide analog of cytosine with potent activity against CMV Foscarnet is given at 90 mg/kg twice daily for two weeks followed by maintenance therapy of 90-120 mg/kg daily through IV infusion. Cidofovir has a longer half life and can be administered weekly during induction followed by bi-weekly maintenance therapy. The dose is 5 mg/kg weekly during induction, and 5 mg/kg every other week during maintenance

•Foscarnet -nephrotoxicity, electrolytes, GU ulcers •Cidofovir -nephrotoxicity, ocular toxicity (uveitis, loss of intraocular pressure) •Combination GCV/FOS (Mylonakis, Clin Infect Dis 2002) •High-dose IV ganciclovir •CMVIg as adjunct to therapy •Reduction of immunosuppression and/or switch to mTOR-based immunosuppressio In month 15, therapy was changed to cidofovir, but after three doses she developed worsening renal insufficiency, and the CMV-DNA viral load rose to 226 000 copies/ml. Resistance to foscarnet and.

Foscarnet Renal, ocular Intravenous CMV, HSV, HPV, pox Di-phosphate Nucleotide analog Cidofovir CMV Intraocular Ocular Parent drug active Antisense oligo-NT: binds to CMV mRNA Formivirsen Topical Ocular HSV keratitis Tri-phosphate Nucleoside analog Idoxuridine Topical Ocular HSV keratitis Tri-phosphate Nucleoside analog Trifluridine Drug. Current treatments are effective (e.g. Cidofovir, ganciclovir and foscarnet) against DNA viruses, but are limited by a number of undesired side effects. For example, Cidofovir (CDV, Vistide) is a nucleoside phosphonate that has broad spectrum antiviral activity against DNA viruses Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The Cytomegalovirus Retreatment Trial. Arch Ophthalmol. 1996;114:23-33. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial Foscarnet has better in vitro efficacy against HHV-6 than ganciclovir, and can pass the blood brain barrier very well. Letermovir was successful in phase 2 trials against CMV in HCT patients, with dosing starting after engraftment. However, it is not effective against HHV-6, which has the highest rate of reactivation after HCT.. Antiviral-resistant or refractory cytomegalovirus (CMV) infection is challenging, and salvage therapies, foscarnet, and cidofovir, have significant toxicities. Several investigational anti-CMV agents are under development, but more information is needed on outcomes of current treatments to facilitate clinical trial design for new drugs

US Food & Drug Administration grants priority review of maribavir for the treatment of post-transplant recipients with cytomegalovirus infection in those resistant and/or refractory to prior anti. foscarnet. Mechanism of action. inhibits viral DNA/RNA polymerase and HIV reverse transcriptase by preventing pyrophosphate from binding. the drug is a pyrophosphate (pyro FOS phate, FOS carnet) analog. does not need to be activated by a kinase. can be used in viral strains resistant to acyclovir and ganciclovir ‡ Resistant defined as refractory CMV and documentation of >1 CMV genetic mutations associated with resistance to ganciclovir, valganciclovir, foscarnet, and/or cidofovir 1. Avery R. Randomized Phase 3 Open-Label Study of Maribavir vs Investigator-Assigned Therapy for Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients. The optimal treatment of these infections is controversial. Second-line antiviral medications (foscarnet and cidofovir) carry high risk for adverse effects, including nephrotoxicity (both foscarnet and cidofovir), electrolyte abnormalities (foscarnet), genitourinary ulcerations (foscarnet), and uveitis (cidofovir)

Avoid direct contact of this medicine with the skin / eyes / mouth. If contact occurs, wash thoroughly with soap and water. For eyes, rinse with a steady stream of tap water for at least 5 minutes. Cidofovir should now be regarded as a treatment option for patients who are failing ganciclovir or foscarnet. In one study, patients who had evidence of disease progression after a median of four re-induction periods with ganciclovir or foscarnet were treated with cidofovir at a dose of 5 mg/kg IV every other week Cidofovir and Foscarnet: Foscarnet therapy is the treatment of choice for ganciclovir-resistant CMV infection. Cidofovir is used to treat CMV retinitis in AIDS patients.To decrease risk of nephrotoxicity, pretreatment with IV fluids and oral probenecid must be given with each cidofovir dose

Cidofovir and Foscarnet for Treatment of Human Herpesvirus

cidofovir iv and foscarnet iv Drug Interactions - RxLis

Raltegravir. Integrase inhibitors, inhibiting integration of viral genome into host cell chromosome. Increased serum creatine kinase. Enfuvirtide. Maraviroc. Fusion inhibitors. Enfuvirtide: inhibits viral entry by binding to viral gp41. Maraviroc: inhibits viral entry by binding CCR-5 on host T-cells, inhibiting its interaction with viral gp120. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment, IAT, (conventional antiviral therapy) in hematopoietic cell transplant and solid organ transplant recipients with CMV infection refractory. Diabetes insipidus is suggested by a history of cancer or chronic granulomatous disease (due to hypercalcemia), use of certain drugs (lithium, cidofovir, foscarnet, ifosfamide), and less common conditions (eg, sickle cell disease, renal amyloidosis, sarcoidosis, Sjögren syndrome) that have manifestations that are often more prominent than and. Unfortunately, such polymerase mutants can demonstrate cross resistance to cidofovir and, rarely, foscarnet. The management of patients with these highly resistant CMV strains can be challenging and may require higher doses of systemic agents, often in combination. In patients treated initially with either foscarnet or cidofovir, the time. Whereas, amino acid substitutions conferring cross-resistance to foscarnet are diverse, but concentrate at and between regions II (codons 696-742) and III (codons 805-845). The amino acid substitutions that resulted in reduced susceptibility to ganciclovir and either cidofovir and/or foscarnet are summarized in Table 11

All-cause mortality at week 24 after transplantation was lower among letermovir recipients than among placebo recipients in the primary efficacy population (10.2% [95% CI, 6.8 to 13.6] vs. 15.9%. FOSCAVIR is the brand name for foscarnet sodium. The chemical name of foscarnet sodium is phosphonoformic acid, trisodium salt. Foscarnet sodium is a white, crystalline powder containing 6 equivalents of water of hydration with an empirical formula of Na 3 CO 5 P•6 H 2 O and a molecular weight of 300.1. The structural formula is

Cidofovir as primary pre-emptive therapy for post

Treatment of an acyclovir and foscarnet-resistant herpes

5600 - CMV Resistance: Ganciclovir, Foscarnet, Cidofovir

The agent of choice is foscarnet. Treatment with CMV immune globulin (CMV IgIV) and cidofovir requires further analysis. The level of immunosuppression should be reduced if possible Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplan Summary Second generation cephalosporins are beta lactam antibiotics. There are four major drugs that are important to remember - cefoxitin, cefaclor, cefuroxime, and cefotetan. Like the first generation cephalosporins, second generation cephalosporins are highly effective against gram-positive cocci like staph and strep bacteria. Key Points - 2nd Generation CephalosporinsDrug.

Recommended options such as cidofovir and foscarnet are associated with a high incidence of nephrotoxicity, often resulting in renal failure in both kidney and non-kidney transplant recipients [12, 13, 18, 19]. Additionally, rejection may also occur as a result of reduced immunosuppression and/or indirect effects associated with CMV infection. Reactivation of human herpesvirus (HHV)-6B is relatively common after allogeneic hematopoietic stem cell transplantation (HSCT) and HHV-6B diseases may consequently develop. Among them, HHV-6B.

Gallant J et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354: 251-60, 2006. Arribas JR et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. Journal. Start studying Cumulative review. Learn vocabulary, terms, and more with flashcards, games, and other study tools Any concomitant therapy that would preclude use of cidofovir, foscarnet or ganciclovir. Prior Medication: Excluded: PER AMENDMENT 4/25/96: Use of IV ganciclovir, foscarnet or cidofovir within 6 months prior to study enrollment. (Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.

- 30 à 100 fois celle du foscarnet - 2 fois moins que le cidofovir • 2 mutations de résistance : UL97 et UL54 • Biodisponibilité orale faible et variable (6-10 %), améliorée par la prise concomitante d'un repas riche en graisses • Prodrogue valganciclovir mieux absorbée (60 % vs herpetic whitlow? Unilocular blister = BDD Multilocular blister = HW. Grouped vesicles/pustules on an erythematous base Foscarnet or cidofovir for acyclovir-resistant HSV (more common in immunosuppressed patients) Boards Factoid What is is the most common caus Cidofovir was the first nucleotide analogue approved for clinical use. The drug has been employed almost exclusively to treat cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS). However, cidofovir is also used as a therapeutic option against other viral infections

Successful treatment with intravesical cidofovir for virus

{{configCtrl2.info.metaDescription}} This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies mechanism of cidofovir nephrotoxicity is intracellular localization of the drug in the proximal tubule. The use of probenecid to block cellular uptake of cidofovir provides renal protection, thereby circumventing the development of nephrotoxicity caused by this agent All acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir. Foscarnet (40-80 mg/kg IV every 8 hours until clinical resolution is attained) is often effective for treatment of acyclovir-resistant genital herpes (368,369). Intravenous cidofovir 5 mg/kg once weekly might also be effective

Antiviral therapy of HSV-1 and -2 - Human Herpesviruses

Cidofovir was used followed by ganciclovir because of an adverse effect to probenecid. The patient recovered. HHV-6 should be recognized as one of the causes of encephalomyelitis. Human herpesvirus 6 (HHV-6) is a member of the Herpesviridae family. Like other members of this family, the virus remains in a latent state after primary infection. Nephrotoxic agents (aminoglycosides, cidofovir, foscarnet, pentamidine): may result in additive nephrotoxicity. Avoid co-administration or use with close monitoring. Pentamidine: potential for additive hypocalcemia and/or nephrotoxicity. Avoid co-administration or use with close monitoring Monotherapy with either ganciclovir or foscarnet. Cidofovir 5 mg/kg IV q wk x 2wks, then dose q2wks (Note: CSF penetration of cidofovir not well studied). The decision to use ganciclovir and/or foscarnet often in part decided upon hematologic and renal aspects Valaciclovir Foscarnet Cidofovir Foscarnet Cidofovir CMV-CTL Letermovir. 36 • EBV infection occurs in over 80-90% of world's population • First human virus implicated in oncogenesis • Remain latent in B-cells • After primary lytic infection, EBV maintains a steady low grade latent infection in the bod

Cytomegalovirus Retinitis: Treatmen

Cidofovir is not an option for HHV6 encephalitis because there is no evidence that it can penetrate to the brain. Although the EC50 of cidofovir is lower, foscarnet has the highest selectivity index or efficacy in vitro for HHV-6 (De Clercq 2001). The drug was originally approved by the FDA in 1991 for AIDS related CMV retinitis Cidofovir Foscarnet Valganciclovir Ganciclovir. On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market. Foscavir puede asociarse con una brusca reducción del calcio sérico ionizado proporcional a la velocidad de perfusión de Foscavir, que puede no reflejarse en los niveles de calcio sérico total. Deberán valorarse los electrolitos, especialmente calcio y magnesio, antes y durante el tratamiento con Foscavir y corregirse las deficiencias Cidofovir therapy can be continued in some patients if medical necessity warrants, but recurrent inflammation or permanent hypotony may occur. References. 1. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the cytomegalovirus retreatment trial ..

PPT - Chapter 12: Urologic Implications of AIDS and HIV

01 Jan 96 CRRT: Combination foscarnet and ganciclovir therapy vs. monotherapy (Arch Ophthalmol) 08 Apr 96 CRRT forms archived SOCA\SOCA Notebooks\CV_Nov11\Manall_3 11:10 am Wednesday, January 11, 2012/klc Chro Selected Nephrotoxic Agents/Cidofovir Interactions . capreomycin, cisplatin, gallium nitrate, foscarnet, high-dose methotrexate, intravenous pentamidine, tenofovir, vancomycin, voclosporin and.

FICHA TECNICA CIDOFOVIR TILLOMED 75 mg/ml CONCENTRADO PARA

Drug-Induced Nephrotoxicity Cynthia a. naughton, PharmD, BCPS, North Dakota State University College of Pharmacy, Nursing, and Allied Sciences, Fargo, North Dakota D rugs cause approximately 20 per Cidofovir One attraction of cidofovir is that it appears to be active against ganciclovir-resistant strains of CMV. Ganciclovir resistance is conferred by mutations in the viral enzyme that mediates monophosphorylation, and because cidofovir requires di- or tri-phosphorylation to become active, ganciclovir-resistant strains usually retain their. They noted that maribavir — an orally bioavailable benzimidazole riboside — is active in vitro against CMV strains resistant to ganciclovir, foscarnet or cidofovir, and has a favorable safety. Codon 300-1000: Confers cross resistance of other drugs (Foscarnet or Cidofovir) UL 54 GCV-CDV (cidofovir) mutation - switch to . foscarnet. UL 54 FOS (foscarnet) mutation - high dose GCV + foscarnet. or . cidofovir. There is little information on the efficacy of cidofovir as salvage therapy in SOT. Kotton, Transplantation, 201

FOSCARNET - FDA prescribing information, side effects and use

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol. to GCV and cross resistance to cidofovir and foscarnet [18,19]. Risk Factors New understanding into the emergence of resistant CMV strains has developed after studies were done by Emery et al. [20,21]. They have shown that in the presence of GCV, mutant CMV strains have a survival advantage compared to wild type CMV. During prolonge It's important to remember that side effects of ganciclovir and valganciclovir can include the suppression of white blood cells (needed to fight infection), red blood cells (that carry oxygen), and platelets (that help the blood to clot). Additionally, cidofovir and foscarnet can cause kidney damage

Cidofovir nephrotoxicity and Probenecid - Renal Fellow Networ

Cross‐resistance of cidofovir and foscarnet has not been identified to date. A broad spectrum agent with in vitro activity against human herpesviruses, adenovirus, HPV, polyomaviruses and human poxviruses, cidofovir is under clinical investigation for a variety of potential applications Conventional antiviral therapy included an investigator assigned treatment of 1 or a combination of the following: ganciclovir, valganciclovir, foscarnet or cidofovir Anti-viral drugs Anti-herpes virus agents• Acyclovir / Valacyclovir• Famciclovir / Penciclovir• Ganciclovir / Cidofovir• Foscarnet• Trifluridine / Idoxuridine / Vidarabine11/18/12 Dr.T.V.Rao MD 15 16

Immunosuppression and Viral Infections | IntechOpenPPT - The polyuric child When we worry? PowerPointSodium-hypo and hyp - Intern Survival Guide

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 July 2021), Cerner Multum™ (updated 1 July 2021), ASHP (updated 30 June. Patients with a TK mutation causing acyclovir resistance can be treated with systemic foscarnet. 200, 201 An HSV resistant to both foscarnet and acyclovir can be effectively treated with cidofovir. 203-208 The role of topical trifluridine in the treatment of acyclovir-resistant, mucocutaneous HSV seemed promising in a pilot study conducted in. In addition to its significant morbidity and mortality, treatment options for GCV-R CMV are also associated with severe adverse outcomes. Recommended options such as cidofovir and foscarnet are associated with a high incidence of nephrotoxicity, often resulting in renal failure in both kidney and non-kidney transplant recipients [12, 13, 18, 19]